
Annual report 2023
added 12-27-2025
Profound Medical Corp. Net Debt 2011-2026 | PROF
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Profound Medical Corp.
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -7.36 M | -18.7 M | -5.96 M | -10.6 M | -3.37 M | 1.31 M | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.31 M | -18.7 M | -7.44 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Medical devices industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Abiomed
ABMD
|
-227 M | - | - | $ 17.2 B | ||
|
Acutus Medical
AFIB
|
14.2 M | - | -26.83 % | $ 2.62 M | ||
|
Allied Healthcare Products
AHPI
|
-3.31 M | - | 3.58 % | $ 2.21 M | ||
|
Apollo Endosurgery
APEN
|
-22.5 M | - | - | $ 475 M | ||
|
Cognyte Software Ltd.
CGNT
|
-47.4 M | $ 9.57 | 0.1 % | $ 687 M | ||
|
GenMark Diagnostics, Inc.
GNMK
|
38.7 M | - | - | $ 1.77 B | ||
|
Alphatec Holdings
ATEC
|
442 M | $ 22.65 | -0.15 % | $ 3.24 B | ||
|
AxoGen
AXGN
|
21.9 M | $ 33.63 | 0.78 % | $ 1.49 B | ||
|
Axonics Modulation Technologies
AXNX
|
-230 M | - | - | $ 3.31 B | ||
|
Apyx Medical Corporation
APYX
|
-10.1 M | $ 3.5 | 1.16 % | $ 121 M | ||
|
EDAP TMS S.A.
EDAP
|
-22.8 M | $ 3.66 | -3.56 % | $ 136 M | ||
|
Electromed
ELMD
|
-10.5 M | $ 28.9 | -0.41 % | $ 244 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
6.46 M | - | -5.86 % | $ 30.6 M | ||
|
Bio-Rad Laboratories
BIO
|
754 M | $ 323.76 | 1.47 % | $ 9.13 B | ||
|
BioSig Technologies
BSGM
|
252 K | - | 37.08 % | $ 85.7 M | ||
|
Boston Scientific Corporation
BSX
|
8.64 B | $ 97.6 | -0.79 % | $ 144 B | ||
|
CONMED Corporation
CNMD
|
889 M | $ 43.07 | -2.56 % | $ 1.33 B | ||
|
Conformis
CFMS
|
-26.2 M | - | - | $ 16.4 M | ||
|
Bruker Corporation
BRKR
|
1.91 B | $ 54.12 | 3.12 % | $ 8.06 K | ||
|
Abbott Laboratories
ABT
|
5.26 B | $ 125.84 | -0.27 % | $ 219 B | ||
|
InMode Ltd.
INMD
|
-34.8 M | $ 14.47 | 1.47 % | $ 1.15 B | ||
|
CryoLife, Inc.
CRY
|
230 M | - | -4.14 % | $ 702 M | ||
|
IRIDEX Corporation
IRIX
|
-4.29 M | $ 1.16 | -2.94 % | $ 18.7 M | ||
|
Cardiovascular Systems
CSII
|
-64.6 M | - | 0.15 % | $ 844 M | ||
|
Cutera
CUTR
|
-140 M | - | -10.19 % | $ 1.99 M | ||
|
LENSAR
LNSR
|
-13.6 M | $ 11.6 | -0.6 % | $ 134 M | ||
|
Soliton, Inc.
SOLY
|
-31.6 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
-9.02 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
-2.3 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
5.72 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
-4.95 M | - | - | $ 111 M | ||
|
Dynatronics Corporation
DYNT
|
1.8 M | - | 14.99 % | $ 929 K | ||
|
Eargo
EAR
|
-97.8 M | - | - | $ 10.2 M | ||
|
Orthofix Medical
OFIX
|
77.8 M | $ 15.77 | -2.65 % | $ 601 M | ||
|
Intersect ENT, Inc.
XENT
|
50.8 M | - | - | $ 955 M | ||
|
Second Sight Medical Products
EYES
|
961 K | - | -0.97 % | $ 54.4 M | ||
|
GBS
GBS
|
-4.38 M | - | -0.57 % | $ 7.12 M | ||
|
Align Technology
ALGN
|
-925 M | $ 172.23 | 0.97 % | $ 12.9 B | ||
|
Accuray Incorporated
ARAY
|
73.7 M | $ 0.89 | -0.47 % | $ 91.5 M | ||
|
IRadimed Corporation
IRMD
|
-52.1 M | $ 98.81 | -1.19 % | $ 1.25 B | ||
|
Avinger
AVGR
|
-16.3 M | - | -20.74 % | $ 369 K | ||
|
ClearPoint Neuro
CLPT
|
-16.5 M | $ 15.06 | -1.63 % | $ 407 M | ||
|
FONAR Corporation
FONR
|
-42.8 M | $ 18.56 | 0.02 % | $ 122 M | ||
|
Sintx Technologies
SINT
|
859 K | $ 3.78 | -1.32 % | $ 14.1 M | ||
|
Sensus Healthcare
SRTS
|
-21.5 M | $ 4.82 | 8.8 % | $ 78.6 M | ||
|
Globus Medical
GMED
|
-774 M | $ 94.0 | -0.66 % | $ 12.8 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
529 M | $ 13.69 | -1.23 % | $ 1.05 B | ||
|
Stryker Corporation
SYK
|
8.68 B | $ 369.46 | 0.61 % | $ 141 B |